Untreated, severe<unk>  has a high risk of death. Modern treatment produces a five-year survival rate that exceeds 85%, with younger age associated with higher survival. Survival rates for stem cell transplants vary depending on the age and availability of a well-matched donor. They are better for patients who have donors that are matched siblings and worse for patients who receive their marrow from unrelated donors. Overall, the five-year survival rate is higher than 75% among recipients of blood marrow transplantation. Older people (who are generally too frail to undergo bone marrow transplants) and people who are unable to find a good bone marrow match have five-year survival rates of up to 35% when undergoing immune suppression. Relapses are common. Relapse following ATG/ciclosporin use can sometimes be treated with a repeated course of therapy. In addition, 10–15% of severe<unk>  cases evolve into myelodysplastic syndrome and leukemia. According to one study, 15.9% of children who responded to immunosuppressive therapy eventually relapsed. Milder disease may resolve on its own.
Aplastic anemia
Acute lymphoblastic leukemia
Refractory anemia with excess of blasts
Polycythemia vera
Myelodysplastic syndrome
Myomatous erythrocytosis syndrome
Essential thrombocythemia
Refractory cytopenia of childhood